The gross margin improvement suggests some pricing power or mix shift, yet the operating margin remains far below the 20%+ levels of top med-tech peers, implying high fixed costs and ongoing remediation expenses. Net margin swung from -24.1% in 2024Q1 to 8.8% in 2026Q2, but this volatility reflects litigation provisions and one-time items, not sustainable earning power. Investors should monitor whether operating leverage can persist without top-line growth, as the flat revenue base limits the scalability of recent margin gains.

The recovery in ROIC is encouraging but still insufficient to create value, as the company's weighted average cost of capital is likely above 7%. The gap between ROIC and peer levels suggests that the litigation and restructuring costs are consuming capital that could otherwise be deployed for growth. With goodwill representing 36% of total assets, there is a risk that future impairments could further erode returns, making the current improvement fragile.

The CCC has improved from 145 days in 2024Q2 but remains well above the 60-80 day range typical for efficient med-tech firms. High inventory days suggest either slow-moving product lines or supply chain disruptions, while DSO indicates slower collections from hospital customers. The company's ability to extend DPO to 84 days provides some offset, but the net working capital drag is a key reason why free cash flow remains volatile and below net income.

The improvement in D/EBITDA is largely due to EBITDA recovery rather than aggressive deleveraging, as total debt only declined by $0.9B over the past year. Interest coverage of 6.75x is adequate but leaves little room for a downturn, especially if litigation settlements require additional cash. The company's debt maturity profile and refinancing needs warrant monitoring, given the potential for higher interest rates to increase the cost of carry.

The quick ratio below 1.0 implies that Philips would struggle to meet short-term liabilities without selling inventory, which is a concern in a stressed scenario. The cash position is small relative to debt, and with litigation payments potentially ongoing, the liquidity buffer could be quickly depleted. However, the company has access to credit lines and a stable service revenue stream, which may provide additional flexibility.